# Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

> **NCT02333162** · PHASE1 · SUSPENDED · sponsor: **University of Chicago** · enrollment: 30 (estimated)

## Conditions studied

- Previously Treated Myelodysplastic Syndrome
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Hematologic Malignancy

## Interventions

- **DRUG:** Fludarabine Phosphate
- **DRUG:** Melphalan
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **RADIATION:** Total Marrow Irradiation
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **PROCEDURE:** Allogeneic Bone Marrow Transplantation
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate Mofetil
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02333162
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2014-12-05
- **Primary completion:** 2028-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Enrollment on hold pending amendment
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02333162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02333162, "Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02333162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*